[HTML][HTML] MYC regulates fatty acid metabolism through a multigenic program in claudin-low triple negative breast cancer

JC Casciano, C Perry, AJ Cohen-Nowak… - British journal of …, 2020 - nature.com
JC Casciano, C Perry, AJ Cohen-Nowak, KD Miller, J Vande Voorde, Q Zhang, S Chalmers
British journal of cancer, 2020nature.com
Background Recent studies have suggested that fatty acid oxidation (FAO) is a key
metabolic pathway for the growth of triple negative breast cancers (TNBCs), particularly
those that have high expression of MYC. However, the underlying mechanism by which
MYC promotes FAO remains poorly understood. Methods We used a combination of
metabolomics, transcriptomics, bioinformatics, and microscopy to elucidate a potential
mechanism by which MYC regulates FAO in TNBC. Results We propose that MYC induces a …
Background
Recent studies have suggested that fatty acid oxidation (FAO) is a key metabolic pathway for the growth of triple negative breast cancers (TNBCs), particularly those that have high expression of MYC. However, the underlying mechanism by which MYC promotes FAO remains poorly understood.
Methods
We used a combination of metabolomics, transcriptomics, bioinformatics, and microscopy to elucidate a potential mechanism by which MYC regulates FAO in TNBC.
Results
We propose that MYC induces a multigenic program that involves changes in intracellular calcium signalling and fatty acid metabolism. We determined key roles for fatty acid transporters (CD36), lipases (LPL), and kinases (PDGFRB, CAMKK2, and AMPK) that each contribute to promoting FAO in human mammary epithelial cells that express oncogenic levels of MYC. Bioinformatic analysis further showed that this multigenic program is highly expressed and predicts poor survival in the claudin-low molecular subtype of TNBC, but not other subtypes of TNBCs, suggesting that efforts to target FAO in the clinic may best serve claudin-low TNBC patients.
Conclusion
We identified critical pieces of the FAO machinery that have the potential to be targeted for improved treatment of patients with TNBC, especially the claudin-low molecular subtype.
nature.com